Paul Daniel Donohoue
University of California, Berkeley
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Paul Daniel Donohoue.
Molecular Cell | 2014
Alexandra E. Briner; Paul Daniel Donohoue; Ahmed A. Gomaa; Kurt Selle; Euan Slorach; Christopher Nye; Rachel E. Haurwitz; Chase L. Beisel; Andrew Paul May; Rodolphe Barrangou
The RNA-guided Cas9 endonuclease specifically targets and cleaves DNA in a sequence-dependent manner and has been widely used for programmable genome editing. Cas9 activity is dependent on interactions with guide RNAs, and evolutionarily divergent Cas9 nucleases have been shown to work orthogonally. However, the molecular basis of selective Cas9:guide-RNA interactions is poorly understood. Here, we identify and characterize six conserved modules within native crRNA:tracrRNA duplexes and single guide RNAs (sgRNAs) that direct Cas9 endonuclease activity. We show the bulge and nexus are necessary for DNA cleavage and demonstrate that the nexus and hairpins are instrumental in defining orthogonality between systems. In contrast, the crRNA:tracrRNA complementary region can be modified or partially removed. Collectively, our results establish guide RNA features that drive DNA targeting by Cas9 and open new design and engineering avenues for CRISPR technologies.
Nature Methods | 2017
Peter Cameron; Christopher K. Fuller; Paul Daniel Donohoue; Brittnee N. Jones; Matthew S. Thompson; Matthew Merrill Carter; Scott Gradia; Bastien Vidal; Elizabeth Garner; Euan Slorach; Elaine Lau; Lynda M Banh; Alexandra M Lied; Leslie S Edwards; Alexander H. Settle; Daniel Capurso; Victor Llaca; Stéphane Deschamps; Mark Cigan; Joshua K. Young; Andrew May
RNA-guided CRISPR–Cas9 endonucleases are widely used for genome engineering, but our understanding of Cas9 specificity remains incomplete. Here, we developed a biochemical method (SITE-Seq), using Cas9 programmed with single-guide RNAs (sgRNAs), to identify the sequence of cut sites within genomic DNA. Cells edited with the same Cas9–sgRNA complexes are then assayed for mutations at each cut site using amplicon sequencing. We used SITE-Seq to examine Cas9 specificity with sgRNAs targeting the human genome. The number of sites identified depended on sgRNA sequence and nuclease concentration. Sites identified at lower concentrations showed a higher propensity for off-target mutations in cells. The list of off-target sites showing activity in cells was influenced by sgRNP delivery, cell type and duration of exposure to the nuclease. Collectively, our results underscore the utility of combining comprehensive biochemical identification of off-target sites with independent cell-based measurements of activity at those sites when assessing nuclease activity and specificity.
Archive | 2014
Andrew Paul May; Rachel E. Haurwitz; Jennifer A. Doudna; James M. Berger; Matthew Merrill Carter; Paul Daniel Donohoue
Trends in Biotechnology | 2017
Paul Daniel Donohoue; Rodolphe Barrangou; Andrew Paul May
Archive | 2015
Andrew May; Paul Daniel Donohoue; Christopher Nye; Euan Slorach; Rachel E. Haurwitz
Archive | 2017
Paul Daniel Donohoue; Andrew Paul May
Archive | 2016
Paul Daniel Donohoue; Andrew Paul May; Katharina Friederike Sonja Stengel
Archive | 2017
Paul Daniel Donohoue; Andrew Paul May
Archive | 2017
Paul Daniel Donohoue; Andrew Paul May
Archive | 2017
Paul Daniel Donohoue; Andrew Paul May